AriBio Completes Patient Dosing in Global Phase 3 Trial of Oral Alzheimer's Drug

AriBio completed final patient dosing in the global Phase 3 trial of AR1001, its oral Alzheimer's drug, across 13 countries, with topline data expected between late September and October.